Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | PLK4 | O00444 | 1/20 | 0.30 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | INSR | P06213 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | ROS1 | P08922 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FER | P16591 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090470 | 1.00 | HCAR1 (0.34) | HCAR1CPB2LMNACYP2C9TSHR | |
| SCHEMBL795718 | 0.87 | — | — | |
| SCHEMBL28321700 | 0.76 | ADORA3 (0.31) | — | |
| SCHEMBL13703133 | 0.75 | CYP11B2 (0.34) | CPB2 | |
| SCHEMBL562133 | 0.74 | PI4KA (0.32) | HCAR1CYP2C9 | |
| SCHEMBL16906227 | 0.73 | — | — | |
| SCHEMBL4585760 | 0.73 | CYP3A4 (0.35) | HCAR1CPB2 | |
| SCHEMBL4944827 | 0.73 | MEN1 (0.40) | CPB2LMNATSHRJAK2 | |
| SCHEMBL7809415 | 0.73 | CYP3A4 (0.35) | HCAR1CPB2 | |
| SCHEMBL3553113 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817284-A4 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-06-26 | — | — | US | disclosed |
| EP-1817284-A2 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057977-A2 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | HCAR1 329/4885CPB2 871/4885LMNA 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.